JASON ROBERT WESTIN to Pyrimidines
This is a "connection" page, showing publications JASON ROBERT WESTIN has written about Pyrimidines.
Connection Strength
0.420
-
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther. 2012 Dec; 11(12):2549-55.
Score: 0.182
-
Ibrutinib and lenalidomide: when 1+1 = >2. Blood. 2019 09 26; 134(13):996-998.
Score: 0.073
-
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018 08; 182(3):404-411.
Score: 0.066
-
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014 Aug; 15(9):1019-26.
Score: 0.051
-
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 01; 105(1):e26-e28.
Score: 0.018
-
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol. 2018 09; 182(5):718-723.
Score: 0.016
-
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.
Score: 0.014